R

Regeneron Pharmaceuticals

Develops biopharmaceutical therapies for serious diseases

Process Sciences Intern - Downstream Purification Support

Summer 2027Updated
$17.90 - $25.50/hr
Internship
Bachelor's, Master's
Rensselaer, NY, USA
In PersonFull-time, onsite in Rensselaer / East Greenbush, New York; internship runs May/June through August.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • Must be enrolled in, or accepted to, an academic program pursuing an undergraduate or graduate degree.
  • Must return to school the semester following the position or graduate after the position.
Responsibilities
  • Contribute to development and operation of manufacturing-scale processes used to grow and purify commercial biologic products.
  • Work on chromatography and filtration techniques, including ultrafiltration and diafiltration, to separate and purify medicine.
  • Run small-scale laboratory experiments, including testing in-line sensors on filtration systems and preparing chromatography solutions in-line.
  • Automate laboratory workflows using liquid-handling robots.
  • Analyze historical manufacturing and laboratory data, including buffer pH and conductivity trends and the effects of downstream process variability on product quality.
  • Use statistical modeling, including design of experiments and multivariate models linking in-line sensor signals to laboratory measurements, and code to create data visualizations and reports.
Desired Qualifications
  • Demonstrated leadership in campus activities, clubs, sports, work, or the community.
  • Cumulative GPA of 3.0 or higher.
  • Interest in process problem-solving; prior industry experience is not required.

About the company

R

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
  • Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
  • Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.

What critics are saying

  • EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
  • Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
  • Dupixent's patent cliff later this decade threatens the company's biggest profit pool.

What makes Regeneron Pharmaceuticals unique

  • VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
  • Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
  • EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Wellness Program
  • Paid Vacation
  • Equity Awards
  • Annual Bonuses
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

1%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 31st, 2026
Regeneron hits two-year high as Dupixent drives $6.5B sales beat, but analysts urge caution

Regeneron Pharmaceuticals shares hit a two-year high on October 30 after a third-quarter earnings beat. The stock is now about 50% above its year-to-date low. Dupixent, developed with Sanofi, brought in roughly $6.5 billion in quarterly sales, against a consensus estimate of $6.1 billion. Regeneron reported earnings per share of $20.07 on revenue of $5.12 billion, both ahead of Street estimates. Earnings rose 70% and revenue 36%. US sales of high-dose Eylea rose 62% to $699 million. Combined US Eylea revenue still fell 1%. Analysts urge caution. Leerink Partners kept a "Market Perform" rating, and the mean price target of about $869 implies roughly 6% downside.

Yahoo Finance
Oct 31st, 2026
Regeneron Q3 revenue jumps 36% to $5.1B as Dupixent and Eylea HD sales surge

Regeneron reported third-quarter 2026 revenue of $5.1 billion, up 36% year over year, on an earnings call on October 30, 2026. Growth came from blockbuster drugs and the company's in-house genetics research engine. Sanofi reported record global Dupixent sales of $6.5 billion, up 35% at constant currency. Regeneron also extended its alliance with Sanofi to co-fund next-generation therapies. US sales of EYLEA HD, a high-dose eye treatment, reached $699 million, up 62%. The drug is offsetting weaker demand for the original formulation. In early data from 40 participants, a gene-silencing therapy for a liver disease cut liver fat by about 70% on average in 12 weeks. Regeneron plans to raise research spending by a mid-teens percentage in 2027 to fund 15 late-stage trials.

Yahoo Finance
Oct 30th, 2026
Regeneron posts record Dupixent, EYLEA HD and Libtayo sales; eyes November FDA decision on cemdisiran

Regeneron Pharmaceuticals reported record quarterly net sales for Dupixent, EYLEA HD, and Libtayo in the third quarter of 2026. It was the third straight quarter of double-digit growth in both revenue and profit. EYLEA HD now makes up nearly two-thirds of the US retinal franchise, with physician demand up 20% sequentially. Libtayo's US sales rose 81%. Regeneron expects a US Food and Drug Administration decision in November on cemdisiran for generalized myasthenia gravis. It would be the first siRNA therapy for the condition. The company expects 2027 research and development spending to rise by a mid-teens percentage to support about 15 Phase 3 trials. It also signalled a shift towards acquiring outside innovation, from early-stage platforms to commercial-stage products. Third quarter Ilaris royalty revenue included a one-off catch-up of about $60 million.

Yahoo Finance
Oct 30th, 2026
Regeneron Q3 revenue jumps 36% to $5.1B as Dupixent and Eylea HD drive growth

Regeneron Pharmaceuticals reported third-quarter revenue of $5.1 billion, up 36% year over year. Non-GAAP diluted earnings per share rose 70% to $20.07, driven by higher Sanofi collaboration revenue and growth in DUPIXENT, EYLEA HD and LIBTAYO. DUPIXENT sold more than $6.5 billion worldwide. EYLEA HD sales rose 62% to $699 million, while legacy EYLEA fell 41% to $400 million amid biosimilar competition. LIBTAYO sales grew 51% to $550 million. The company expects a US Food and Drug Administration decision in November on cemdisiran for generalized myasthenia gravis. It plans more than 15 Phase III trial starts in 2026. Regeneron expects a $1 billion upfront payment from Sanofi in the fourth quarter. It ended the quarter with $16.2 billion in cash and marketable securities, net of debt.

Yahoo Finance
Oct 30th, 2026
Regeneron jumps 13.55% on Q3 earnings beat as revenue climbs 36% to $5.1B

Regeneron shares jumped 13.55% to $929.69 on October 30, 2026, after third-quarter results beat expectations. Non-GAAP earnings per share were $20.07 against a $16.19 consensus estimate, and revenue rose 36% year over year to $5.12 billion. Sanofi collaboration revenue climbed 68% to $2.72 billion. US sales of EYLEA HD rose 62% and Libtayo grew 51%, while the company raised its full-year non-GAAP gross margin guidance to about 86%. The rally lifted sector funds. The Health Care Select Sector SPDR Fund (XLV) gained 1.8% and the iShares Biotechnology ETF (IBB) rose 1.25%. Regeneron expects a US Food and Drug Administration decision on cemdisiran next month.